Corxel Inks $300 Million Merger With Amanat

Supported by $300 million in expected gross proceeds from a private investment in public equity (PIPE) commitment, clinical-stage biopharmaceutical company Corxel Pharmaceuticals (Corxel US) signed a definitive merger agreement with Nasdaq-listed special purpose acquisition company Amanat Acquisition Corp (Nasdaq: AMAN). Under the agreement dated October 26, 2026, high-demand PIPE financing will be deployed in addition to approximately $75 million in funds held in Amanat's trust account.

What is the financial size of the Corxel and Amanat merger?

Upon completion of the transaction, Corxel US will become a wholly owned subsidiary of the publicly traded combined entity. Shares of the new parent company will trade on the Nasdaq Capital Market under a new ticker symbol and a new corporate name. While the appointment of a new US-based chief executive officer is targeted prior to or concurrently with the closing, Corxel US's existing management team will continue to lead the company.

How will the clinical timeline progress for the CX11 obesity drug?

Institutional investors including RTW Investments, New Enterprise Associates (NEA), SR One, Mirae Asset Capital Life Science and RA Capital Management participated in the financing round. The provided resources will fund global pivotal Phase 3 clinical trials for Corxel US's once-daily oral small-molecule GLP-1 candidate CX11 for obesity treatment. Having completed End-of-Phase 2 discussions with the FDA, the company's portfolio also includes the CX12 oral amylin program.

Amanat Acquisition shares, currently trading on the Nasdaq market under the ticker AMAN, will be replaced by a new ticker symbol following the merger; no data regarding immediate price and volume movements on the trading board was shared in the official company announcement.

This content is for information purposes only and does not constitute investment advice.